Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Consolidated Net Income (2023 - 2025)

Historic Consolidated Net Income for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$1.9 million.

  • BioLineRx's Consolidated Net Income rose 4941.52% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year increase of 5725.76%. This contributed to the annual value of -$19.3 million for FY2024, which is 5942.77% up from last year.
  • BioLineRx's Consolidated Net Income amounted to -$1.9 million in Q3 2025, which was up 4941.52% from -$2.0 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Consolidated Net Income ranged from a high of -$1.9 million in Q3 2025 and a low of -$19.5 million during Q4 2023
  • Moreover, its 3-year median value for Consolidated Net Income was -$5.4 million (2024), whereas its average is -$6.7 million.
  • Over the last 5 years, BioLineRx's Consolidated Net Income had its largest YoY gain of 6734.38% in 2024, and its largest YoY loss of 3149.2% in 2024.
  • Over the past 3 years, BioLineRx's Consolidated Net Income (Quarter) stood at -$19.5 million in 2023, then skyrocketed by 59.28% to -$7.9 million in 2024, then skyrocketed by 76.03% to -$1.9 million in 2025.
  • Its Consolidated Net Income stands at -$1.9 million for Q3 2025, versus -$2.0 million for Q2 2025 and -$2.0 million for Q1 2025.